Literature DB >> 1979241

Prophylactic treatment of grass pollen-induced asthma with cetirizine.

J H Dijkman1, P R Hekking, J F Molkenboer, G Nierop, R Vanderschueren, J Bernheim, E H Van Ganse.   

Abstract

In a double-blind randomized parallel-group study, six investigators enrolled 43 subjects to study the prophylactic effect of 10 mg cetirizine b.i.d. on grass pollen-induced asthma. The control group received 60 mg b.i.d. terfenadine, given to avoid withdrawals from the trial because of hay fever symptoms. Subjects were included in the study between the appearance of the first symptoms of hay fever and those of pollen-induced asthma. The hay fever and asthma symptoms, visual analogue scores (VAS), FEV1 and self-assessment data on complaints, salvage treatment and peak-flow values were statistically analysed. Both treatments were well tolerated, with a low and similar incidence of side-effects. During the last 3 weeks of treatment, six (32%) of the 19 subjects on cetirizine who were evaluable for efficacy remained free of asthma complaints, and another two (10%) had only a single minor attack. None had a grade 3 (incapacitating) attack. Conversely, only one (5%) of the 20 evaluable subjects on terfenadine remained complaint free, and all others (95%) had multiple attacks, which incapacitated three (15%) of them. Nasal obstruction, dyspnoea, morning peak flow, consumption of beta 2-mimetics and an efficacy index on asthma, combining complaints and rescue drug consumption, were significantly better on cetirizine (P less than 0.05). It is concluded that cetirizine is able to prevent the exacerbation of asthma induced by grass pollen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979241     DOI: 10.1111/j.1365-2222.1990.tb03140.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  8 in total

Review 1.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

3.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria.

Authors:  D M Campoli-Richards; M M Buckley; A Fitton
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

5.  Effects of cetirizine on isolated rat's tracheal smooth muscle.

Authors:  Chuan-Hsiang Kao; Yueng-Hsiang Chu; Hsing-Won Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-10-22       Impact factor: 2.503

6.  A double-blind, placebo controlled study of the effect of the specific histamine H1-receptor antagonist, terfenadine, in chronic severe asthma.

Authors:  R Wood-Baker; R Smith; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

7.  Effect of longterm cetirizine treatment on the cutaneous hypersensitivity reaction in patients with grass pollen allergy.

Authors:  J R Snyman; D K Sommers; M van Wyk; D J Lizamore
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 8.  Cetirizine use in childhood: an update of a friendly 30-year drug.

Authors:  Giuseppe Fabio Parisi; Salvatore Leonardi; Giorgio Ciprandi; Angelo Corsico; Amelia Licari; Michele Miraglia Del Giudice; Diego Peroni; Carmelo Salpietro; Gian Luigi Marseglia
Journal:  Clin Mol Allergy       Date:  2020-02-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.